Geoffrey Porges
Stock Analyst at SVB Leerink
(1.34)
# 3,483
Out of 4,902 analysts
122
Total ratings
42.35%
Success rate
-7.21%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geoffrey Porges
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Maintains: Market Perform | $52 → $56 | $24.58 | +127.83% | 10 | Dec 15, 2021 | |
| RCUS Arcus Biosciences | Maintains: Outperform | $68 → $100 | $9.42 | +961.57% | 8 | Nov 18, 2021 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $798 → $850 | $550.00 | +54.55% | 16 | Nov 5, 2021 | |
| HALO Halozyme Therapeutics | Maintains: Outperform | $50 → $48 | $57.81 | -16.96% | 2 | Nov 3, 2021 | |
| AMGN Amgen | Maintains: Market Perform | $234 → $216 | $298.25 | -27.58% | 12 | Nov 3, 2021 | |
| ABBV AbbVie | Maintains: Outperform | $142 → $135 | $191.40 | -29.47% | 16 | Nov 1, 2021 | |
| ROIV Roivant Sciences | Initiates: Outperform | $11 | $11.65 | -5.54% | 1 | Nov 1, 2021 | |
| GILD Gilead Sciences | Maintains: Outperform | $77 → $75 | $108.80 | -31.07% | 14 | Oct 29, 2021 | |
| SNY Sanofi | Upgrades: Outperform | n/a | $48.65 | - | 2 | Sep 27, 2021 | |
| TBPH Theravance Biopharma | Maintains: Outperform | $29 → $10 | $11.62 | -13.94% | 9 | Sep 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $875 → $750 | $8.07 | +9,193.68% | 8 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $170 → $175 | $463.27 | -62.23% | 9 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $96 → $84 | $19.30 | +335.23% | 3 | May 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $36.47 | - | 1 | Mar 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $3.41 | +867.74% | 1 | Nov 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $61 | $8.01 | +661.55% | 2 | Nov 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $128.69 | - | 8 | Mar 16, 2017 |
Pfizer
Dec 15, 2021
Maintains: Market Perform
Price Target: $52 → $56
Current: $24.58
Upside: +127.83%
Arcus Biosciences
Nov 18, 2021
Maintains: Outperform
Price Target: $68 → $100
Current: $9.42
Upside: +961.57%
Regeneron Pharmaceuticals
Nov 5, 2021
Maintains: Outperform
Price Target: $798 → $850
Current: $550.00
Upside: +54.55%
Halozyme Therapeutics
Nov 3, 2021
Maintains: Outperform
Price Target: $50 → $48
Current: $57.81
Upside: -16.96%
Amgen
Nov 3, 2021
Maintains: Market Perform
Price Target: $234 → $216
Current: $298.25
Upside: -27.58%
AbbVie
Nov 1, 2021
Maintains: Outperform
Price Target: $142 → $135
Current: $191.40
Upside: -29.47%
Roivant Sciences
Nov 1, 2021
Initiates: Outperform
Price Target: $11
Current: $11.65
Upside: -5.54%
Gilead Sciences
Oct 29, 2021
Maintains: Outperform
Price Target: $77 → $75
Current: $108.80
Upside: -31.07%
Sanofi
Sep 27, 2021
Upgrades: Outperform
Price Target: n/a
Current: $48.65
Upside: -
Theravance Biopharma
Sep 16, 2021
Maintains: Outperform
Price Target: $29 → $10
Current: $11.62
Upside: -13.94%
Aug 10, 2021
Maintains: Outperform
Price Target: $875 → $750
Current: $8.07
Upside: +9,193.68%
Jul 30, 2021
Maintains: Underperform
Price Target: $170 → $175
Current: $463.27
Upside: -62.23%
May 10, 2021
Maintains: Market Perform
Price Target: $96 → $84
Current: $19.30
Upside: +335.23%
Mar 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $36.47
Upside: -
Nov 11, 2020
Initiates: Outperform
Price Target: $33
Current: $3.41
Upside: +867.74%
Nov 28, 2018
Initiates: Outperform
Price Target: $61
Current: $8.01
Upside: +661.55%
Mar 16, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $128.69
Upside: -